AU2019409269B2 - Methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate active compound product having improved properties, production and formulation thereof - Google Patents

Methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate active compound product having improved properties, production and formulation thereof Download PDF

Info

Publication number
AU2019409269B2
AU2019409269B2 AU2019409269A AU2019409269A AU2019409269B2 AU 2019409269 B2 AU2019409269 B2 AU 2019409269B2 AU 2019409269 A AU2019409269 A AU 2019409269A AU 2019409269 A AU2019409269 A AU 2019409269A AU 2019409269 B2 AU2019409269 B2 AU 2019409269B2
Authority
AU
Australia
Prior art keywords
active compound
wetting agent
formula
water
compound product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019409269A
Other languages
English (en)
Other versions
AU2019409269A1 (en
Inventor
Guido Becker
Joerg BROCKOB
Peter Fey
Markus Longerich
Heike Neumann
Michal SOWA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adverio Pharma GmbH
Original Assignee
Adverio Pharma GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adverio Pharma GmbH filed Critical Adverio Pharma GmbH
Publication of AU2019409269A1 publication Critical patent/AU2019409269A1/en
Application granted granted Critical
Publication of AU2019409269B2 publication Critical patent/AU2019409269B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2019409269A 2018-12-17 2019-12-16 Methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate active compound product having improved properties, production and formulation thereof Active AU2019409269B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18213115.1 2018-12-17
EP18213115 2018-12-17
PCT/EP2019/085255 WO2020126983A1 (en) 2018-12-17 2019-12-16 Methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate active compound product having improved properties, production and formulation thereof

Publications (2)

Publication Number Publication Date
AU2019409269A1 AU2019409269A1 (en) 2021-06-03
AU2019409269B2 true AU2019409269B2 (en) 2025-04-03

Family

ID=64744472

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019409269A Active AU2019409269B2 (en) 2018-12-17 2019-12-16 Methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate active compound product having improved properties, production and formulation thereof

Country Status (19)

Country Link
US (1) US12172996B2 (enExample)
EP (1) EP3898624A1 (enExample)
JP (1) JP7529667B2 (enExample)
KR (1) KR102872983B1 (enExample)
CN (1) CN113207290B (enExample)
AR (1) AR116912A1 (enExample)
AU (1) AU2019409269B2 (enExample)
BR (1) BR112021009122A2 (enExample)
CL (1) CL2021001580A1 (enExample)
CO (1) CO2021007668A2 (enExample)
IL (1) IL283976B2 (enExample)
JO (1) JOP20210155B1 (enExample)
MX (1) MX2021007090A (enExample)
PE (1) PE20211593A1 (enExample)
SG (1) SG11202104953VA (enExample)
TW (1) TWI830835B (enExample)
UA (1) UA129677C2 (enExample)
WO (1) WO2020126983A1 (enExample)
ZA (1) ZA202105021B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI830835B (zh) 2018-12-17 2024-02-01 德商亞德維瑞醫藥有限公司 具改善性質之{4,6-二胺基-2-[5-氟-1-(2-氟芐基)-1H-吡唑並[3,4-b]吡啶-3-基]嘧啶-5-基}胺基甲酸甲酯活性化合物產物、其製造及調配物
WO2021156223A1 (en) 2020-02-03 2021-08-12 Adverio Pharma Gmbh Nanoformulations of methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate
EP3925953A1 (en) 2020-06-16 2021-12-22 Adverio Pharma GmbH Process for preparing methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate
WO2025114276A1 (en) 2023-12-01 2025-06-05 Krka, D.D., Novo Mesto Solid oral composition comprising vericiguat

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013076168A1 (de) * 2011-11-25 2013-05-30 Bayer Pharma Aktiengesellschaft Verfahren zur herstellung von substituierten 5-fluor-1h-pyrazolopyridinen

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2745813B1 (fr) 1996-03-07 1998-05-07 Rhone Poulenc Chimie Agglomerats spheriques d'acide 10-phenothiazinylpropanoique et leur procede de preparation
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
UY33041A (es) 2009-11-27 2011-06-30 Bayer Schering Pharma Aktienegesellschaft Procedimiento para la preparaciòn de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo y su purificaciòn para el uso como principio activo farmacèutico
DK3415515T3 (da) 2009-11-27 2020-03-16 Adverio Pharma Gmbh Fremgangsmåde til fremstilling af methyl-{4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}methylcarbamat
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
CA2901636A1 (en) * 2013-02-21 2014-08-28 Adverio Pharma Gmbh Forms of methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate
PL2792682T3 (pl) 2013-04-19 2017-04-28 Zach System Sposób wytwarzania stałej postaci octanu abirateronu
WO2016113415A1 (en) * 2015-01-16 2016-07-21 Sandoz Ag Process for the preparation of riociguat essentially free from genotoxic impurities
WO2017025981A1 (en) * 2015-08-13 2017-02-16 Msn Laboratories Private Limited Process for the preparation of methyl 4,6-diamino-2-[l-(2-fhiorobenzvr)-lh-pyrazolo i3,4-blpvridin-3-vn-5-pyrimidinyl(methvl)carbamate and its polymorphs thereof
TWI830835B (zh) 2018-12-17 2024-02-01 德商亞德維瑞醫藥有限公司 具改善性質之{4,6-二胺基-2-[5-氟-1-(2-氟芐基)-1H-吡唑並[3,4-b]吡啶-3-基]嘧啶-5-基}胺基甲酸甲酯活性化合物產物、其製造及調配物
EP3914588A1 (en) 2019-01-22 2021-12-01 Adverio Pharma GmbH Process for manufacturing 4-(2,2,3,3-tetrafluoropropyl)morpholine
WO2021156223A1 (en) * 2020-02-03 2021-08-12 Adverio Pharma Gmbh Nanoformulations of methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate
EP3925953A1 (en) * 2020-06-16 2021-12-22 Adverio Pharma GmbH Process for preparing methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013076168A1 (de) * 2011-11-25 2013-05-30 Bayer Pharma Aktiengesellschaft Verfahren zur herstellung von substituierten 5-fluor-1h-pyrazolopyridinen

Also Published As

Publication number Publication date
CO2021007668A2 (es) 2021-07-19
ZA202105021B (en) 2026-05-27
BR112021009122A2 (pt) 2021-08-10
CN113207290B (zh) 2024-04-09
US20220048907A1 (en) 2022-02-17
TW202039488A (zh) 2020-11-01
US12172996B2 (en) 2024-12-24
PE20211593A1 (es) 2021-08-18
KR20210104703A (ko) 2021-08-25
EP3898624A1 (en) 2021-10-27
MX2021007090A (es) 2021-08-11
TWI830835B (zh) 2024-02-01
AU2019409269A1 (en) 2021-06-03
IL283976B2 (en) 2025-04-01
UA129677C2 (uk) 2025-07-02
SG11202104953VA (en) 2021-06-29
JOP20210155A1 (ar) 2023-01-30
WO2020126983A1 (en) 2020-06-25
CN113207290A (zh) 2021-08-03
CA3123360A1 (en) 2020-06-25
JOP20210155B1 (ar) 2025-10-01
CL2021001580A1 (es) 2021-12-03
KR102872983B1 (ko) 2025-10-17
JP2022515376A (ja) 2022-02-18
JP7529667B2 (ja) 2024-08-06
AR116912A1 (es) 2021-06-23
IL283976A (en) 2021-07-29
IL283976B1 (en) 2024-12-01

Similar Documents

Publication Publication Date Title
US12172996B2 (en) Methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate active compound product having improved properties, production and formulation thereof
AU2015358497B2 (en) Anticancer compositions
EP3226841B1 (en) Anticancer compositions
CN110382467B (zh) 结晶药物产品的制备
EA023286B1 (ru) Способ получения полиморфной формы i эторикоксиба
TWI904746B (zh) 具有改良溶解度之新穎瓦莫洛龍(vamorolone)製劑
JP4498679B2 (ja) 結晶性イソキサゾール誘導体およびその医薬製剤
RU2818488C2 (ru) Продукт активного соединения метил { 4,6-диамино-2-[5-фтор-1-(2-фторбензил)-1H-пиразоло[3,4-b]пиридин-3-ил]пиримидин-5-ил} карбамата, имеющий улучшенные свойства, его получение и состав
HK40050973B (en) Active compound product having improved properties, production and formulation thereof
HK40050973A (en) Active compound product having improved properties, production and formulation thereof
JP4684545B2 (ja) 溶出性の良好なイソキサゾール誘導体経口製剤
JP2023545808A (ja) 再加工方法
WO2023174937A1 (en) Particles comprising non-crystalline odevixibat
HK40109507B (en) A new vamorolone preparation exhibiting improved solubility
HK40109507A (en) A new vamorolone preparation exhibiting improved solubility

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period
NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO REQUEST EXAMINATION HAS BEEN EXTENDED TO 19 DEC 2023

FGA Letters patent sealed or granted (standard patent)